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Abstract
BACKGROUND—Critical shortages of organs for transplantation jeopardize many lives. 
Observational data suggest that better fluid management for deceased organ donors could increase 
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organ recovery. We conducted the first large multi-center randomized trial in brain-dead donors to 
determine whether protocolized fluid therapy increases organs transplanted.
METHODS—We randomly assigned donors to either protocolized or usual care in eight organ 
procurement organizations. A “protocol-guided fluid therapy” algorithm targeting cardiac index, 
mean arterial pressure and pulse pressure variation was used. Our primary outcome was the 
number of organs transplanted per donor and our primary analysis was intention-to-treat. 
Secondary analyses included: 1) modified intention-to-treat where only subjects able to receive the 
intervention were included, and 2) twelve-month survival in transplant recipients. The study was 
stopped early.
RESULTS—We enrolled 556 donors; 279 protocolized care, 277 usual care. Groups had similar 
characteristics at baseline. The study protocol could be implemented in 76% of subjects 
randomized to the intervention. There was no significant difference in mean number of organs 
transplanted per donor: 3.39 organs per donor, (95%CI: 3.14-3.63) with protocolized care, 
compared to usual care 3.29 (95%CI: 3.04-3.54) (mean difference, 0.1, 95%CI: -0.25 to 0.45; 
p=0.56). In modified intention-to-treat analysis the mean number of organs increased (3.52 organs 
per donor, 95%CI: 3.23-3.8) but was not statistically significant (mean difference, 0.23, 95%CI: 
-0.15-0.61; p=0.23). Among the 1430 recipients of organs from study subjects, with data available, 
56 deaths (7.8%) occurred in the protocolized care arm and 56 (7.9%) in the usual care arm in the 
first year (Hazard Ratio: 0.97, p=0.86).
CONCLUSIONS—In brain-dead organ donors, protocol-guided fluid therapy compared to usual 
care may not increase the number of organs transplanted per donor.
Keywords
Organ donation; clinical trial; transplantation; functional hemodynamic monitoring; fluid 
management; brain death
Despite efforts to increase organ donation [1-4], there remains a critical shortage in both 
organ donors and organs transplanted per donor [5, 6]. Strategies to increase recovery of 
organs from donors are therefore urgently needed. Compared to historical controls, donor 
management with increased attention to fluid resuscitation has been shown to reduce 
cardiovascular collapse and increase the number of organs transplanted per donor [7]. 
However, excessive fluid may also cause organ edema. Optimal management of donor 
hemodynamics, as in the live patient, aims to achieve euvolemia, maintain blood pressure, 
and attain a cardiac output to achieve gradients of perfusion pressure and blood flow that 
promote organ function with minimal use of vasoactive-drug support. While there are 
several reasons why not all potential organs are donated and subsequently transplanted, 
hemodynamic instability of the donor is an important and modifiable factor.
One method to assess fluid optimization is to examine the Pulse Pressure Variation (PPV) 
while receiving positive pressure mechanical ventilation [8-11]. We previously reported an 
association between increased PPV, indicating fluid responsiveness, and increased levels of 
inflammatory mediators in the donor [12]. Furthermore, increased concentrations of the 
circulating inflammatory mediator interleukin (IL)-6 in donors was shown to predict six-
month hospital-free survival in recipients [13]. We therefore conducted the first large 
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multicenter randomized trial (MOnIToR) in brain-dead donors to determine if protocolized 
fluid therapy would increase organs transplanted, and improve survival in the recipients 
compared to usual care.
METHODS
Detailed study methods and statistical analysis plan have been published previously [14]. 
Abbreviated methods follow.
Study Oversight
From October 8, 2009 to March 23, 2013, we enrolled organ donors cared for by organ 
procurement coordinators from eight organ procurement organizations (OPOs) in the US. 
The trial was approved by each participating OPO scientific committee with oversight by the 
University of Pittsburgh Committee for Oversight of Research and Clinical Training 
Involving Decedents (CORID). Where required, additional approval by local institutional 
review boards was sought.
LiDCO Ltd provided equipment education, training and support. An external advisory 
committee was assembled and included content experts and an independent statistician. The 
committee was chaired by an investigator outside of the coordinating center and not 
affiliated with any participating OPO (RP). The committee reviewed study conduct and the 
results of the interim analysis and made recommendations to the MOnIToR executive 
committee. This study used data from the Scientific Registry of Transplant Recipients 
(SRTR). The SRTR data system included data on all donors, wait-listed candidates and 
transplant recipients in the US, submitted by the members of the Organ Procurement and 
Transplantation Network (OPTN), and has been described elsewhere [15]. The Health 
Resources and Services Administration (HRSA), U.S. Department of Health and Human 
Services provides oversight to the activities of the OPTN and SRTR contractors. All the 
authors vouch for the integrity and the accuracy of the analysis and for the fidelity of the 
study to the protocol.
Selection of Subjects
Subjects were older than 16 years of age, were declared brain dead and were considered 
eligible for organ donation. An arterial catheter in place or a plan to place one was also 
required for enrollment. Donors were excluded from the study when research consent was 
not granted or there was inability to perform minimally invasive hemodynamic monitoring. 
Patients receiving lithium therapy; known severe aortic regurgitation, intra-cardiac shunts, 
or on intra-aortic balloon pump; receiving extracorporeal membrane oxygenation or 
ventricular assist device support were also excluded.
Intervention
After obtaining research consent, entry criteria and other baseline data was entered into a 
web-based enrollment application. Donors were assigned a study identification number and 
treatment allocation. Randomization was 1:1 into each arm, achieved using a web-based 
randomization system. Randomization was stratified according to the donor's age ≥65 vs. 
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<65. In the usual care arm, the donor was managed according to local standards, which did 
not include functional hemodynamic monitoring. In the protocolized arm, a non-invasive 
hemodynamic monitor (LiDCO Plus, LiDCO Ltd, London, UK) was connected to the 
donor's indwelling arterial catheter and calibrated. A protocol guiding fluid therapy (Figure 
1) was followed until transfer to the operating room for organ procurement.
Outcome Measures and Definitions
The primary outcome measure was the number of organs transplanted per donor. Secondary 
outcomes included: i) Number of organs recovered regardless of whether transplanted; ii) 
The observed (O) versus expected (E) organs transplanted (O/E) ratio; iii) Recipient survival 
to six months and iv) Six month hospital-free survival (6mHFS) in recipients—defined as 
recipient survival in days after transplantation in the first 6 months (6mHFS = days alive up 
to 180 days after transplantation minus index hospital length of stay in days).
Statistical Analysis
Our primary analysis was an intention-to-treat (ITT) analysis of the mean number of organs 
transplanted per donor in each group with one interim and a final analysis. As described 
previously [14], we planned in advance for a modified intention-to-treat (mITT) analysis 
where only subjects able to receive the intervention were included in the protocolized care 
arm (excluding donors when devices were unavailable, incompatible with local hospital 
equipment, or where technical problems unrelated to the subjects precluded use of the 
device). In addition we planned for a ‘responder’ analysis where donors in the protocol arm 
were judged to have responded to care by protocol. This determination was made by 
consensus of three investigators (AA, RM, JAK) based on changed in hemodynamics 
including PPV and blinded to study outcomes as previously described [14]. Finally, we 
calculated the observed (O) versus expected (E) organs transplanted (O/E) ratio as 
previously described [16]. A detailed description of this metric has been reported previously 
[14, 16].
The study was designed to enroll 960 subjects in order to detect a difference of 0.5 organs 
per donor assuming a mean of 3.1 organs transplanted per donor. A single interim analysis 
was conducted after accrual of 50% of the initially planned subjects (480). Results of 
Interim Analysis were forwarded to the Executive Steering committee, who determined that 
the trial did not meet the stopping criteria set by O'Brien-Fleming criterion, and the study 
was continued until March 23, 2013 when study resources would be exhausted.
Donor characteristics between Protocolized and Usual Care groups were compared using 
Wilcoxon's test for continuous data (e.g., Age) and chi-square tests with correction for 
continuity for categorical variables or its exact version, or the Fisher's test as appropriate. 
The primary endpoint of number of organs transplanted was presented using the mean and 
95% Wald confidence intervals separately for the two arms, and the mean difference 
between the two arms were tested using two-sample two-sided t-test. The secondary 
endpoints of number of organs recovered and the observed/expected ratio was analyzed 
using same statistical methods.
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The secondary endpoint six-month hospital free survival (6mHFS) was analyzed using 
survival analysis methodology as some recipients were lost to follow up before 180 days. 
Kaplan-Meier survival curves were used to visually investigate the differences in the 
distribution of 6mHFS between the two arms while log-rank test was used to compare 
differences between two arms. A Cox proportional hazard model was used to quantify the 
hazard ratio and the results were presented as point estimate and 95% confidence interval. 
Overall recipient survival was calculated as the time from transplant to death. Since many of 
the recipients were censored, the analysis was limited to 12-month follow-up after 
transplantation. Usual methods of survival analysis, namely, Kaplan-Meier curves, log-rank 
test, and Cox model was used respectively to investigate the survival pattern across arms, to 
test the difference in distribution, and to quantify the hazard ratio. We conducted two pre-
planned subgroup analyses examining expanded criteria donors (ECD) vs. standard criteria 
and age ≥65 vs <65 separately.
Sensitivity Analyses
Aborted cases (e.g. discovery of metastatic cancer or various infections or serology) are 
typically excluded from the assessment of number of organs transplanted from each donor. 
For all primary and secondary analyses aborted cases were excluded. However, as a 
sensitivity analysis we also reran our primary and secondary analyses considering aborted 
cases as having contributed zero organs.
Provider survey
In order to elucidate the opinions of the bedside coordinators as to relative ease of delivering 
the intervention, we conducted a brief post-study survey. The survey questions are provided 
in the supplement (Table S3).
RESULTS
Study subjects
We enrolled 556 brain dead organ donors; 279 were randomly assigned to protocolized care 
and 277 to usual care. Study flow is shown in Figure 2; 48 donors were aborted after 
randomization by the OPOs per standard protocols (e.g. a donor found to have metastatic 
cancer). No follow-up data are available on aborted cases. Characteristics of the remaining 
508 donors are shown in Table 1 and are well balanced between groups. Protocolized care 
was associated with increased use of fluids. However, there were no differences in 
vasoactive medication use between the two groups (Table 2)
Number of organs transplanted
The distribution of organs transplanted from each group is shown in Table 3. We found no 
significant difference in the mean number of organs transplanted per donor with 3.39 (95% 
CI: 3.14-3.63) organs per donor in the protocolized care arm compared to 3.29 (3.04-3.54) 
organs per donor in the usual care arm (mean difference, 0.10, 95%CI: -0.25 to 0.45; 
p=0.56). In the mITT analysis the mean number of organs transplanted per donor increased 
(3.52 organs per donor, 95%CI: 3.23-3.8) but was not statistically significant (mean 
difference, 0.23, 95%CI: -0.15-0.61; p=0.23). Finally, in the ‘responder’ analysis the mean 
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number of organs transplanted per donor increased further to 3.87±2.16 bringing the mean 
difference to 0.58±2.07 (95% CI -0.02 to 1.19; p=0.059). These results are illustrated in 
Figure 3.
Preplanned subgroup and sensitivity analyses
The mean number of organs transplanted from standard criteria donors was nearly identical 
by study arm: 3.92 for protocolized and 3.94 for usual care; p=0.96. For the ECD group, 
1.83 organs were transplanted from protocolized care versus 1.66 for usual care (difference 
0.16 (-0.30 to 0.63); p=0.49. Only 52 donors were ≥65 years of age and the mean number of 
organs transplanted was 1.0 for both study groups. We performed sensitivity analyses 
repeating ITT and mitt analysis where aborted cases were considered to have contributed 
zero organs (rather than being excluded). The results were very similar to the analysis 
presented above (data not shown).
Recipient outcomes
Among the 1476 recipients (740 in Protocolized Care and 736 in Usual Care) of organs from 
study subjects for whom data were available from SRTR, 1430 (718 in Protocolized Care 
and 712 in Usual Care) had survival data available. Of these, within the first 12 months of 
transplantation, 56 deaths (7.8%) occurred in the protocolized care arm and 56 (7.9%) in the 
usual care arm [Hazard Ratio: 0.97 (0.66-1.42), p=0.86. Survival curves for recipients of 
organs from donors in the ITT and mITT cohorts are shown in Figure S2. No statistically 
significant differences were observed between treatment arms in either group.
Finally, the distribution of six-month hospital-free survival was almost identical between 
recipients of organs from protocolized and usual care donors with median (25th percentile, 
75th percentile) 171 (164-175) vs. 171 (163-174) days (p=0.35).
Post-study provider survey
Results of our survey are provided in the supplement (Table S3). Notably, while more than 
50% of procurement coordinators found the protocol easy to follow, none (0%) classified 
the hemodynamic monitor device as ‘easy’ to use. While the protocol was implemented in 
76% of subjects randomized to the intervention, only about a third of coordinators reported 
strictly adhering to the protocol.
DISCUSSION
MOnIToR is the only large multicenter randomized controlled trial of organ donor 
management published to date. Our results demonstrate that protocolized fluid therapy is not 
superior to usual care whether considering a strict ITT or a modified ITT analysis. Although 
these results are disappointing several important findings should be noted. First, large scale, 
multicenter, pragmatic trials have not been the norm in donor management. Prior studies 
have generally been small and single-center investigations [7, 17, 18] and outcomes have 
often been limited to short term organ functional assessments. This has led to adoption of 
clinical practices based on low-level evidence. For example, thyroid hormone has been 
commonly used in organ donors based on small case series. A recent meta-analysis of four 
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existing RCTs (n=209) showed no benefit [19]. Similar results have been reported with 
corticosteroids [20]. Other trials have focused on specific organs. Mascia and colleagues 
randomized 118 potential lung donors across 12 centers to a lung protective ventilation 
strategy and reported a doubling (from 27% to 54%) of the number of organs transplanted 
without impacting six-month recipient survival [21]. Low-tidal volume ventilation was not 
standard for donors our trial. Similarly, Schnuelle and colleagues conducted a randomized, 
open-label, multicenter, parallel-group trial of 264 brain-dead kidney donors and found that 
low-dose dopamine infusion resulted in less dialysis in the recipients [22]. Our study 
demonstrates that large pragmatic trials are feasible in donors—using sample sizes necessary 
for detecting realistic effect sizes.
Second, though our study demonstrates feasibility, complex interventions that rely on skilled 
operators or, as in our study, availability and functionality of equipment, are less well suited 
to this area of medicine [23-26]. Organ procurement coordinators have difficult jobs caring 
for donors at different institutions with different types of cardiac monitors and different 
cultures.
Third, as to the effect of the intervention itself, the effect size, if there is any, is likely to be 
smaller than hypothesized. The mITT analysis likely reflects the “best case scenario” and 
showed a point estimate for difference between groups of 0.23 organs (95%CI: -0.15-0.61; 
p=0.23). Thus the true effect, while possibly reaching 0.5 organs is more likely about half 
this difference. In order to find a difference of only 0.23 organs we would have required a 
sample size of 4182 donors. A trial of this magnitude was beyond our resources and would 
have required involvement of many more OPOs. Finally, although an increase of 0.23 
organs per donor extrapolates to a nearly 7% increase in available organs, which could result 
in thousands of lives saved, it nevertheless falls short of the desired impact. New 
interventions that increase organ yield such as therapeutic hypothermia [27-29] are being 
studied. However, given the magnitude of the problem and the potential for benefit, new 
interventions are needed.
Our protocolized fluid therapy was provided on a background of routine hemodynamic 
management. Prior to our study and to date, there is no consensus regarding the use of 
inotropes in the management of donors and therefore it was not possible to protocolize this 
aspect of care. Our study protocol focused on fluids and vasopressors and left inotropes and 
other agents at the discretion of the clinicians managing the donor. However, our analysis of 
protocol “responders” suggests that efforts to improve donor hemodynamics are likely 
worthwhile. Indeed responders nearly achieved a significant improvement in the number of 
organs used and the point estimate was greater than the originally hypothesized difference of 
0.5 organs. Unfortunately less than a third of donors (29%) randomized to the intervention 
met our criteria for response, suggesting that either more effective interventions are needed 
or that some donors do not have modifiable hemodynamics.
We have faced several challenges conducting the study, some were expected and have been 
reported previously [30-32]. Our study highlights the fact that complex interventions are 
challenging and perhaps simpler interventions could prove to be more effective in achieving 
goals of donor care. Despite the extensive training we provided, some coordinators had 
Al-Khafaji et al. Page 7













difficulties with LiDCO calibration and many felt that it was time consuming. In our post-
study survey it was clear that none of the providers felt that the intervention was easy and 
more than 40% classified it as hard. Indeed, only 76% of donors randomized to the 
intervention were able to receive it because of logistical problems including cable 
incompatibility, calibration problems or simply the lack of equipment on site. Although 
most found the protocol itself easy to follow, a simpler monitor system might have 
facilitated delivery of the intervention.
Unfortunately, it will take several years before new treatments can be developed and new 
trials can be conducted. While we await these developments we continue to be faced with an 
ever-increasing demand for organs and an ever-growing number of potential recipients 
dying for lack of these organs. For those practitioners using protocol-guided fluid therapy it 
is reassuring that our intervention did not appear to reduce organs in any subgroup or 
secondary analysis. Neither were any differences seen in major recipient outcomes such as 
length of hospitalization or 1-year survival. This suggests that recipients of organs taken 
from protocolized care donors fared as well as those receiving organs from usual care and 
that the extra 0.1 organs “rescued” by the intervention (or 0.3 in the mITT analysis) did not 
result in lower quality of organs transplanted. Indeed it is notable that in subgroup analysis, 
extended-criteria donors accounted for all the effect seen in the ITT analysis where again a 
smaller absolute, but similar relative (about 10%), increase was observed but failed to reach 
significance.
In conclusion, compared to usual care, protocolized fluid therapy on a background of routine 
hemodynamic management did not increase the number of organs transplanted from brain 
dead organ donors. More effective (and perhaps easier to implement) strategies are needed. 
Our trial demonstrates the feasibility of studying such interventions using a network of 
OPOs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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MOnIToR protocol-guided hemodynamic management
PPV: pulse-pressure variation; CI: cardiac index; MAP: mean arterial pressure.
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ITT: intention-to-treat; mITT: modified intention-to-treat; OPO: organ procurement 
organization.
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Results of Primary and Secondary Analyses. Shown are differences in mean number of 
organs transplanted (top) and differences in the ratio of observed versus predicted organs per 
donor (bottom). Positive difference favors the protocolized arm; nP and nU are the sample 
sizes in the protocolized and usual care arms respectively. ITT: intention-to-treat; mITT: 
modified intention-to-treat.
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Table 1
Donor characteristics by Intervention Arm
Donor Characteristics All (n = 508)^ Protocolized Arm (n=249) Usual Care Arm (n=259) p-value#
Age in years 44(29, 56) 43(29, 55) 46(28, 56) 0.35
Donor Race 0.49
Black or African American 65(12.8) 31(12.4) 34(13.1)
White 419(82.5) 209(83.9) 210(81.1)
Other 24(4.7) 9(3.6) 15(5.8)
Donor ABO 0.78*
A1: A1 91(17.9) 49(19.7) 42(16.2)
A1B: A1B 5(1) 4(1.6) 1(0.4)
A2: A2 10(2) 3(1.2) 7(2.7)
A2B: A2B 1(0.2) 0(0.0) 1(0.4)
A: A 88(17.3) 38(15.3) 50(19.3)
AB: AB 9(1.8) 4(1.6) 5(1.9)
B: B 52(10.2) 29(11.6) 23(8.9)
O: O 252(49.6) 122(49) 130(50.2)
Donor Gender 0.84
Female 241(47.4) 117(47) 124(47.9)
Male 267(52.6) 132(53) 135(52.1)
Donor History of Diabetes 0.22**
1: NO 451(88.8) 224(90) 227(87.6)
2: YES, 0-5 YEARS 20(3.9) 11(4.4) 9(3.5)
3: YES, 6-10 YEARS 10(2) 2(0.8) 8(3.1)
4: YES, >10 YEARS 25(4.9) 12(4.8) 13(5)
5: YES, DURATION UNKNOWN 2(0.4) 0(0.0) 2(0.8)
Donor hypertension 0.94
No 295(58.3) 145(58.5) 150(58.1)
Yes 211(41.7) 103(41.5) 108(41.9)
Donor history of hypertension 0.98
1: NO 297(58.5) 145(58.2) 152(58.7)
2: YES, 0-5 YEARS 94(18.5) 46(18.5) 48(18.5)
3: YES, 6-10 YEARS 41(8.1) 19(7.6) 22(8.5)
4: YES, >10 YEARS 56(11) 30(12) 26(10)
5: YES, UNKNOWN DURATION 18(3.5) 8(3.2) 10(3.9)
998: UNKNOWN 2(0.4) 1(0.4) 1(0.4)
Donor Meets Expanded Criteria 0.42
No 370(73) 185(74.6) 185(71.4)
Yes 137(27) 63(25.4) 74(28.6)
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Donor Characteristics All (n = 508)^ Protocolized Arm (n=249) Usual Care Arm (n=259) p-value#




Patient characteristics of 48 aborted donors were not available;
#
From two-sided t-test for Age, from Chi-square test for others;
*
Based on A, B, AB, and O, p-value = exact Chi-square test
**
p-value = exact Chi-square test
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Table 2
Use of fluid and medications by intervention arm
Variable Protocolized Care Usual Care P Value
Fluids infused (ml) 1,229.10 986.18 0.037
Mean (SD) (2,502.12) (2,195.98)
Medications used (%)
Antihypertensives 56 (24.9) 56 (22.2) 0.49
Vasodilators 14 (6.6) 9(3.5) 0.13
DDAVP 67 (29.6) 79 (30.86) 0.77
Vasopressin 121 (53.5) 130 (50.5) 0.52
Inotropes/vasopressor 195 (49.8) 196 (50.1) 0.72
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Table 3
Number of organs transplanted by intervention arm
Number of Organs Transplanted Intervention Total (508)
Protocolized Care N=249 Usual Care N=259
0 20(8.03) 21(8.11) 41
1 28(11.24) 38(14.67) 66
2 28(11.24) 39(15.06) 67
3 65(26.1) 47(18.15) 112
4 38(15.26) 43(16.60) 81
5 28(11.24) 29(11.20) 57
6 24(9.64) 21(8.11) 45
7 15(6.02) 17(6.56) 32
8 3(1.20) 4(1.54) 7
Summary Difference
Mean (sd) 95% CI 3.39(1.97) (3.14, 3.63) 3.29(2.05) (3.04, 3.54) 0.10(2.01) (−0.25, 0.45)
p-value from t-test (pooled) t506 = 0.58, p =0.56
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